CEO Update | 20 February 2023

I’m looking forward to seeing many of you at this year's BIA Committee Summit this Thursday – always a vibrant and engaging event with BIA member expertise overflowing the venue – which this year is Church House in Westminster. The idea of the day is for each of our expert Advisory Committees to hold their first meeting of the year in the same place at the same time – so they can come together in a plenary session to understand common themes and make connections. The social at the end of the day also helps with serendipitous mixing.

Department for Science, Innovation and Technology

More detail on the new Department for Science, Innovation and Technology (DSIT) is emerging – both in terms of senior civil service leadership and priorities set for the department by the Prime Minister. Priority outcome one is well aligned with the work we’ve been doing on increasing investment into innovative UK life science businesses: “optimise public R&D investment to support areas of relative UK strength and increase the level of private R&D to make our economy the most innovative in the world”. With George Freeman in the Minister of State role, we know he’ll bring his experience and expertise from our sector to bear on this agenda.

Spring Budget

On the Westminster front policy activity ahead of the Spring budget is hotting up as the competing priorities on the HM Treasury purse become clearer by the day. We continue to make the case for a supportive business environment for life science-based startups and scaleups – and I’m looking forward to meeting MPs in the Houses of Parliament tomorrow evening to highlight the opportunity for the UK to be a leader in synbio for human health. The event is being held by the Parliamentary and Scientific Committee APPG in partnership with bit.bio which is good to see.

Northern Ireland Protocol

I’m also keeping a close eye on developments in the Northern Ireland Protocol, which are expected to move this week. The BIA has worked hard on the complex regulatory issues with a focus on medicines down the years and UK government officials and ministers are well aware of our preferred approach. This week will see if Rishi Sunak’s government are able to broker a deal with politicians in Northern Ireland and their backbenchers that can unlock important developments for the sector like the UK’s participation in Horizon Europe.
 

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates

CEO Update | 27 March 2023

The UK Government published last week the long-awaited response to the consultation on proposals to improve the UK clinical trials legislation, with a foreword by life science champions Sir John Bell and Sir Jon Symonds. These reforms represent the biggest overhaul in UK clinical trials regulation in over 20 years and will make the UK one of the best countries to conduct clinical research for the benefit of patients and the life sciences sector. Continue reading for details on upcoming events, UK Parliament scrutiny of SVB Collapse, and more.

Revolutionising healthcare with data-driven innovation

Meet Danny Bosch, Associate Director of Business Development and Commercial at Imperial College Health Partners (ICHP). In his blog, Danny details how ICHP are working towards creating healthier populations, by unlocking the potential of innovation and supporting NHS and industry. 

Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therapy for the treatment of cancer

Worldwide drug discovery collaboration agreement with Ono to develop new antibody drugs against a novel macrophage target of interest in immuno-oncology

Brainomix receives FDA clearance for its flagship stroke AI imaging software

The Oxford, UK headquartered company, long established as a market leader in Europe and a pioneer in the development of innovative stroke AI solutions, is now poised to take its transformative technology to US stroke centers

Unlocking the power of Virtual Reality to overcome anxiety and phobias

XR Therapeutics is a start-up company, spun out of Newcastle University, helping people to overcome their phobias or anxiety using Virtual Reality technology. We spoke with Penny Day, Head of Operations, about the role of virtual reality in mental health treatment, and how XR is making waves in this space.

CEO Update | 20 March 2023

The Budget last week had major wins for BIA members including changes to R&D tax credits rates for loss-making SMEs. Read our press release and Martin’s analysis blog. This is a major, major win for a BIA campaign and wouldn’t have happened without member engagement and perseverance. Many thanks to all who helped – this non dilutive government co-investment will make all the difference as you crowd in private sector investment.

More within